Editas Medicine (EDIT) Other financing activities (2016 - 2025)
Editas Medicine (EDIT) posted quarterly Other financing activities of $228000.0 for Q2 2025, up 75.38% year-over-year from $130000.0 in Q2 2024, and down 14.93% quarter-over-quarter from $268000.0 in Q4 2024.
Editas Medicine (EDIT) Other financing activities (2016 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Other financing activities for 10 consecutive years, with $228000.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Other financing activities rose 75.38% year-over-year to $228000.0; the TTM figure through Sep 2025 stood at $496000.0 (down 38.46% YoY), while the FY2024 annual figure was $590000.0, down 35.8% from the prior year.
- Other financing activities retreated to $228000.0 in Q2 2025 per EDIT's latest filing, from $268000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $16.6 million in Q2 2021 and bottomed at $130000.0 in Q2 2024.
- Historically, Other financing activities has averaged $2.6 million across 5 years, with a median of $430000.0 in 2021.
- Annual changes were most pronounced in 2021 — Other financing activities surged 293.9% — and 2022, when it slumped 99.1%.
- Editas Medicine's Other financing activities stood at $430000.0 in 2021, then jumped by 42.33% to $612000.0 in 2022, then slipped by 20.92% to $484000.0 in 2023, then sank by 44.63% to $268000.0 in 2024, then slipped by 14.93% to $228000.0 in 2025.
- Business Quant data shows EDIT's Other financing activities at $228000.0 in Q2 2025, $268000.0 in Q4 2024, and $130000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 228,000.00 |
| Jun 30, 2025 | 228,000.00 |
| Dec 31, 2024 | 268,000.00 |
| Dec 31, 2024 | 268,000.00 |
| Jun 30, 2024 | 130,000.00 |
| Jun 30, 2024 | 130,000.00 |
| Mar 31, 2024 | 192,000.00 |
| Mar 31, 2024 | 192,000.00 |
| Dec 31, 2023 | 484,000.00 |
| Dec 31, 2023 | 484,000.00 |
| Jun 30, 2023 | 435,000.00 |
| Jun 30, 2023 | 435,000.00 |
| Dec 31, 2022 | 612,000.00 |
| Dec 31, 2022 | 612,000.00 |
| Jun 30, 2022 | 149,000.00 |
| Jun 30, 2022 | 149,000.00 |
| Mar 31, 2022 | 218,000.00 |
| Mar 31, 2022 | 218,000.00 |
| Dec 31, 2021 | 430,000.00 |
| Dec 31, 2021 | 430,000.00 |